Wegovy Patient Assistance for Low-Income: Every Program, Step by Step

Why Wegovy Costs So Much, and Why That Price Is Negotiable

Wegovy carries a monthly list price near $1,349 without insurance, placing it out of reach for most uninsured or underinsured adults who meet clinical criteria for treatment. That clinical bar is meaningful: the FDA approved Wegovy in June 2021 for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Prescribing information is available via the FDA label database.

The cost is high partly because semaglutide remains under patent protection through the mid-2030s. Novo Nordisk holds exclusive manufacturing rights, so no FDA-approved generic exists yet.

What the Clinical Evidence Justifies

The price conversation matters more when you understand what the drug actually does. In the STEP-1 randomized controlled trial (N=1,961), adults receiving semaglutide 2.4 mg subcutaneously once weekly achieved a mean body-weight reduction of 14.9% at 68 weeks, compared with 2.4% in the placebo group (P<0.001). The full STEP-1 trial was published in the New England Journal of Medicine.

A second key study, STEP-4 (N=803), showed that patients who continued semaglutide maintained their weight loss, while those switched to placebo regained an average of 6.9% of body weight over the following 48 weeks. STEP-4 results are available on PubMed.

Why This Matters for Assistance Eligibility

Because the clinical benefit is well-documented, payers and assistance programs have increasingly been willing to cover the drug. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "anti-obesity medications should be prescribed as an adjunct to lifestyle modification for patients with obesity or overweight with weight-related comorbidities." The full guideline is published through the Endocrine Society. That language gives prescribers a strong basis for medical necessity letters when appealing insurance denials.

The Novo Nordisk NovoCare Patient Assistance Program

NovoCare is Novo Nordisk's own patient assistance program. It provides Wegovy at no cost to qualifying uninsured or underinsured patients. As of early 2026, the income ceiling sits at or below 400% of the Federal Poverty Level (FPL), though Novo Nordisk has discretion to approve cases above that threshold on a case-by-case basis. Program details are maintained on the NovoCare website.

Who Qualifies

To be considered, a patient generally must:

• Be a U.S. Resident with a valid prescription from a licensed prescriber.
• Have no insurance coverage for Wegovy, or have insurance that denies coverage.
• Meet the income threshold (roughly $58,000 for an individual in 2026, scaling up with household size).
• Not be enrolled in a federal health program that would cover the drug (Medicare Part D, Medicaid, TRICARE).

How to Apply

The application process has three steps. First, the prescribing provider's office initiates the paperwork, since NovoCare verifies prescriber information directly. Second, the patient submits proof of income, typically the most recent federal tax return or three months of pay stubs. Third, Novo Nordisk ships approved medication directly to the prescriber's office or, in some cases, to the patient's home pharmacy.

Processing typically takes two to four weeks. Approvals are valid for 12 months and require annual renewal with updated income documentation.

What to Do If You Are Denied

A denial is not final. If your income exceeds the standard threshold by a modest amount, your prescriber can submit a medical necessity letter citing the STEP-1 and STEP-4 data along with your specific comorbidities. The FDA's patient assistance program guidance acknowledges that manufacturers set their own eligibility criteria and may grant exceptions.

Novo Nordisk Savings Card for Commercially Insured Patients

For patients who have commercial (private) insurance, including employer-sponsored plans and ACA marketplace plans, Novo Nordisk offers a co-pay savings card that can bring the monthly out-of-pocket cost to as low as $0, subject to a monthly cap and an annual program limit.

How the Card Works

The savings card functions as a secondary payer. After your insurance processes the claim and assigns a co-pay, the card covers the remaining balance up to the stated monthly maximum. Patients with high-deductible health plans benefit most during their deductible phase.

Eligibility restrictions are significant. The card is not available to patients enrolled in Medicare Part D, Medicaid, TRICARE, or any other federal health program. That restriction is a legal requirement under the federal anti-kickback statute, not a Novo Nordisk policy choice. The OIG guidance on co-pay assistance in federal programs explains this constraint.

Activating and Stacking Benefits

The savings card is activated at NovoCare.com or through the prescriber's office. Some specialty pharmacies activate it automatically when they fill the prescription. Patients can stack the savings card on top of a GoodRx or similar discount card only if the prescription is processed as cash-pay rather than through insurance, using both simultaneously on an insurance claim violates program terms and federal law.

Medicare and Medicaid Coverage in 2026

Medicare Part D

Medicare historically excluded weight-loss drugs from Part D coverage under the Social Security Act. That changed with the Inflation Reduction Act and subsequent CMS rulemaking. Starting January 1, 2026, Medicare Part D plans are permitted to cover FDA-approved anti-obesity medications, including Wegovy, when prescribed for obesity (BMI 30 or greater) or overweight with a qualifying comorbidity. CMS published the final rule details in the Federal Register, with summary guidance on the CMS website.

Coverage is not automatic. Individual Part D plans determine their own formulary placement, and Wegovy may be on a non-preferred tier with a substantial co-pay unless the plan has negotiated a preferred tier arrangement. During open enrollment each year, patients should use the Medicare Plan Finder tool to compare plans by their Wegovy tier status and estimated annual out-of-pocket cost.

Medicaid

Medicaid coverage varies by state. As of 2026, approximately 13 states have explicitly added FDA-approved anti-obesity medications to their Medicaid preferred drug lists. Another 19 states cover them with prior authorization. The remaining states either exclude the drug class or have pending rulemaking. State Medicaid formulary data is maintained through the Medicaid Drug Rebate Program database on CMS.gov.

A prior authorization for Medicaid typically requires documentation of BMI, at least one weight-related comorbidity, a record of prior lifestyle intervention (usually 3 to 6 months of documented counseling), and a letter of medical necessity from the prescriber.

Compounded Semaglutide: The $199/Month Alternative

When brand-name Wegovy is unavailable or unaffordable, FDA-regulated 503B outsourcing facilities may compound semaglutide. The average price from licensed compounders sits near $199/month, roughly 85% less than the Wegovy list price.

The FDA's Evolving Position

The FDA placed semaglutide on its drug shortage list in 2022 due to manufacturing constraints. Under federal law, 503B outsourcing facilities and 503A pharmacies may compound drugs that appear on the shortage list. In February 2025, the FDA announced it had determined that the shortage was resolved for semaglutide injection products used for weight management, which triggered a phase-out period for compounded versions. The FDA's shortage resolution notice is available on the FDA drug shortage database.

That resolution created legal uncertainty. Some 503B facilities challenged the determination in federal court, and as of early 2026 the regulatory picture remains in flux. Patients and prescribers should verify the current legal status of compounded semaglutide before initiating therapy. The FDA's guidance on compounding from bulk substances is available on FDA.gov.

Safety and Dose Accuracy

Compounded semaglutide is not FDA-approved and has not undergone the same manufacturing quality controls as Wegovy. The FDA has received adverse event reports linked to compounded versions, including dosing errors from vials labeled in units rather than milligrams. The FDA's safety alert on compounded semaglutide is on FDA.gov.

If a patient and prescriber decide to pursue a compounded product, the prescriber should confirm the compounder holds 503B status with the FDA, request a Certificate of Analysis for each lot, and specify the dose in milligrams (not units) on the prescription.

State and Federal Extra Help Programs

Medicare Low Income Subsidy (Extra Help)

Medicare beneficiaries with limited income and resources may qualify for the Low Income Subsidy (LIS), also called Extra Help. In 2026, full Extra Help covers Part D premiums, deductibles, and most co-pays, capping Wegovy co-pays at roughly $11.20 per fill for generic-tier drugs or $35 for brand-tier drugs. Eligibility and application details are on SSA.gov.

Full LIS is automatically assigned to patients receiving Medicaid, SSI, or Medicare Savings Program benefits. Others can apply online through the Social Security Administration.

State Pharmaceutical Assistance Programs (SPAPs)

Roughly 24 states operate SPAPs that supplement Medicare Part D coverage. New Jersey's PAAD program, for example, caps monthly drug costs at $10 for qualifying low-income seniors. Program rules differ substantially by state. A current list of state SPAPs is maintained by the Medicare Rights Center.

Appealing an Insurance Denial

Insurance denials for Wegovy are common, but the appeal success rate is meaningful when the paperwork is thorough. A 2023 analysis published in JAMA Health Forum found that patients who submitted peer-to-peer physician reviews alongside their appeals had significantly higher approval rates than those who submitted written appeals alone. The JAMA Health Forum analysis is available through the JAMA Network.

Building the Appeal

A strong appeal packet includes:

• A letter of medical necessity from the prescriber citing BMI, relevant ICD-10 codes (E66.01 for morbid obesity, for example), and specific comorbidities.
• Documentation of prior lifestyle intervention, at minimum 3 months of records from a registered dietitian or physician-supervised program.
• Reference to the STEP-1 trial data showing 14.9% mean weight loss at 68 weeks. Full trial data is available at NEJM.org.
• The Endocrine Society guideline language supporting pharmacotherapy as adjunctive treatment.

External Review Rights

Under the ACA, patients whose internal appeal is denied have the right to an independent external review by a third party. External reviews are binding on the insurer. The timeline is 45 to 60 days for standard reviews, or 72 hours for urgent/expedited cases involving active medical need. ACA external review rights are summarized on HealthCare.gov.

The HealthRX Access Decision Framework

The table below maps a patient's insurance situation to the most likely access pathway. Use it as a starting checklist before calling the pharmacy or prescriber's office.

| Insurance Situation | First Step | Second Step | Estimated Monthly Cost | |---|---|---|---| | Uninsured, income <400% FPL | Apply to NovoCare PAP | Confirm shipment to prescriber | $0 (if approved) | | Commercially insured, Wegovy covered | Activate savings card at NovoCare.com | Use preferred specialty pharmacy | $0 to $25 | | Commercially insured, Wegovy denied | File internal appeal with STEP-1 data | Request peer-to-peer review | Varies pending outcome | | Medicare Part D | Check formulary tier on Plan Finder | Apply for Extra Help if income qualifies | $11 to $200 depending on tier/LIS | | Medicaid, state covers AOMs | Submit prior auth with BMI and comorbidities | Document 3-6 months lifestyle intervention | $0 to $10 co-pay | | Medicaid, state excludes AOMs | Contact state Medicaid agency for exceptions | Consider 503B compounded semaglutide (verify legal status) | $150 to $250 compounded | | Any situation, interim need | Verify 503B compounder FDA registration | Request Certificate of Analysis for lot | ~$199 |

Choosing a Specialty Pharmacy

Most insurers and the NovoCare program require Wegovy to be dispensed through a specialty pharmacy rather than a standard retail chain. Accredo, CVS Specialty, and Novo Nordisk's own Novo Nordisk Direct program are the most commonly contracted options as of 2026.

Specialty pharmacies provide nurse-educator support, injection training resources, and automated refill reminders. That support matters clinically: adherence at 12 months in STEP-1 was 94.3% for semaglutide vs. 89.6% for placebo. See the supplementary appendix of the STEP-1 publication at NEJM.org.

Patients should call their specialty pharmacy before the first fill to confirm which payment pathway is active, savings card, PAP shipment, or insurance billing, and to verify the co-pay amount. A mismatch at the pharmacy counter is one of the most common reasons patients abandon the first fill.

What Prescribers Can Do

Prescribers are not passive participants in the access process. A 2022 Obesity journal survey found that 67% of patients who successfully accessed GLP-1 receptor agonists reported that their prescriber's office completed at least part of the prior authorization paperwork on their behalf. The Obesity journal is accessible through PubMed.

Practices with a dedicated prior authorization coordinator reduce patient abandonment rates substantially. Prescribers should also be aware that the American Gastroenterological Association (AGA) and the Obesity Medicine Association (OMA) both publish prior authorization templates specifically for semaglutide, available free to member clinicians. The AGA's clinical resources are listed at gastro.org.

The Endocrine Society guideline notes directly: "Clinicians should advocate for insurance coverage of anti-obesity medications for patients with obesity or overweight with weight-related comorbidities." Source: Endocrine Society 2023 guideline, published in JCEM.

Keeping Track: Programs Change Frequently

Every program described in this article is subject to revision. Novo Nordisk adjusted the savings card income cap twice between 2022 and 2024. Several state Medicaid programs added Wegovy to their preferred drug lists in late 2025 after CMS issued updated guidance. The 503B compounding field shifted after the FDA's 2025 shortage resolution announcement and may shift again pending litigation.

Patients should verify current terms at:

• NovoCare.com for the savings card and PAP.
• Medicare.gov Plan Finder for Part D formulary status.
• Their state Medicaid agency's pharmacy benefit website for current PDL status.
• The FDA drug shortage database for compounding legal status.

Verifying before filling saves time, co-pay surprises, and unnecessary prescription abandonment.